Innovative genetic technology solutions can be brought to market faster through industrial partnerships. This was announced by the Russian Minister of Education and Science, Valery Falkov, after the meeting of the working group on legal regulation in the field of genetics and bioethics. The meeting was held at the R&D center of the biotechnology company BIOCAD.
The main discussion was about attracting industrial partners for clinical trials of innovative drugs within the framework of the Federal Scientific and Technical Program for the Development of Genetic Technologies 2019-2030. Ethical dimensions and regulating the activities of independent ethics committees were also brought up.
The minister emphasized that the development of genetic technologies is important for scientific and economic progress. This area impacts the economy, science, and drug safety. Research support helps in the fight against serious diseases and in the creation of innovative medicines.
Pavel Yakovlev, Deputy Director General of BIOCAD, shared the experience of the company in cooperation with the Pirogov Medical University. Their joint work led to the creation of an innovative drug to combat Bechterew’s disease. This experience highlighted the effectiveness of the interaction between academic science and business.
BIOCAD is a company that manufactures drugs for the treatment of oncological, autoimmune and other diseases. The company is committed to the development of new drugs using genetic technologies.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
